{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:45:55Z","timestamp":1759333555315},"reference-count":52,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2007,6,19]],"date-time":"2007-06-19T00:00:00Z","timestamp":1182211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2007,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Vascular endothelial growth factor (VEGF) and its endothelial cell receptors (VEGFR) have been shown to be involved in the pathogenesis of the contact hypersensitivity (CHS) reaction. Previous studies have demonstrated that anti\u2010VEGFR\u20102 antibody significantly suppresses the elicitation phase of CHS but does not affect the induction phase. PTK787\/ZK 222584 (1\u2010[4\u2010chloroanilino]\u20104\u2010[4\u2010pyridylmethyl] phthalazine succinate; <jats:italic>PTK\/ZK<\/jats:italic>) is a potent inhibitor of VEGFR tyrosine kinases. To test the effect of <jats:italic>PTK\/ZK<\/jats:italic> on the induction and elicitation phases of CHS separately, we used an established method of CHS assay\u2010sensitization and challenge in BALB\/c mice. Either 50\u00a0mg\/kg\/day <jats:italic>PTK\/ZK<\/jats:italic> or vehicle serving as a control was administered orally in the induction or elicitation phases separately. In the afferent phase, flow cytometry of skin\u2010draining lymph node cells revealed that the migration of Langerhans cells was suppressed in the mice treated with <jats:italic>PTK\/ZK<\/jats:italic> at sensitization. The degrees of ear swelling at 24 and 48\u00a0h were significantly diminished in mice treated with <jats:italic>PTK\/ZK<\/jats:italic> at sensitization (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05). In the efferent phase, the degrees of ear swelling at 24\u00a0h (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.01) and 48\u00a0h (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05), ear blood flow at 24 and 48\u00a0h (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.01), and production of VEGF in the epidermis at 24\u00a0h (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05) were significantly suppressed in mice treated with <jats:italic>PTK\/ZK<\/jats:italic> at elicitation. These findings and previous demonstrations suggest that both VEGF R\u20101 and VEGF R\u20102 are needed during the induction phase, and that VEGFR\u20102 has a pivotal role in the elicitation phase of the CHS reaction.<\/jats:p>","DOI":"10.1111\/j.1346-8138.2007.00304.x","type":"journal-article","created":{"date-parts":[[2007,6,20]],"date-time":"2007-06-20T03:29:11Z","timestamp":1182310151000},"page":"419-429","source":"Crossref","is-referenced-by-count":5,"title":["Vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787\/ZK 222584 inhibits both the induction and elicitation phases of contact hypersensitivity"],"prefix":"10.1111","volume":"34","author":[{"given":"Aisaku","family":"YAMAMOTO","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"WATANABE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohiko","family":"SUEKI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako","family":"NAKANISHI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"YASUHARA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"IIJIMA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,6,19]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.144.11.4121"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.3.1001"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.1992.tb03768.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1089\/10799900252952181"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.6.3079"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.166.6.1654"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.145.9.2833"},{"key":"e_1_2_6_9_2","first-page":"1508","volume-title":"Immune Mechanisms of Allergic Contact Dermatitis","author":"Cumberbatch M","year":"2000"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-2427(00)00204-X"},{"issue":"2","key":"e_1_2_6_11_2","first-page":"41","article-title":"Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy","volume":"60","author":"Wood JM","year":"2000","journal-title":"Medicina"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-0348-9006-9_10"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.140.4.947"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115568"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/27.13.2569"},{"key":"e_1_2_6_16_2","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.4049\/jimmunol.154.6.2801","article-title":"Overexpression of vascular permeability factor (VPF\/VEGF) and its endothelial cell receptors in delayed hypersensitivity skin reactions","volume":"154","author":"Brown LF","year":"1995","journal-title":"J Immunol"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0906-6705.2004.00240.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-08-2964"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64773-6"},{"key":"e_1_2_6_20_2","first-page":"3158","article-title":"VEGF is major stimulator in model of choroidal neovascularization","volume":"41","author":"Kwak N","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_6_21_2","first-page":"2178","article-title":"PTK787\/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor\u2010induced responses and tumor growth after oral administration","volume":"60","author":"Wood JM","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.6494907"},{"key":"e_1_2_6_23_2","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.4049\/jimmunol.155.8.3801","article-title":"Effect of gene\u2010targeted mutation in TNF receptor (p55) on contact hypersensitivity and ultraviolet B\u2010induced immunosuppression","volume":"155","author":"Kondo S","year":"1995","journal-title":"J Immunol"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12325538"},{"key":"e_1_2_6_25_2","first-page":"1996","article-title":"Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer","volume":"62","author":"Baker CH","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.176.1.47"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.2002.01381.x"},{"key":"e_1_2_6_28_2","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.4049\/jimmunol.159.12.6148","article-title":"Depressed Langerhans cell migration and reduced contact hypersensitivity response in mice lacking TNF receptor p75","volume":"159","author":"Wang B","year":"1997","journal-title":"J Immunol"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9610(89)90694-6"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.3109\/02844317909013034"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04274.x"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2005.tb00794.x"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)52451-6"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197111182852108"},{"key":"e_1_2_6_35_2","first-page":"4015","article-title":"PTK787\/ZK 222584, a specific vascular endothelial growth factor\u2010receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging","volume":"62","author":"Drevs J","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.03.005"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.2.538"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004030000193"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1078\/0171-9335-00252"},{"key":"e_1_2_6_40_2","first-page":"RE21","article-title":"VEGF receptor signal transduction","volume":"112","author":"Matsumoto T","year":"2001","journal-title":"Sci STKE"},{"key":"e_1_2_6_41_2","first-page":"765","article-title":"Neovasculature induced by vascular endothelial growth factor is fenestrated","volume":"57","author":"Roberts WG","year":"1997","journal-title":"Cancer Res"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.59.1.100"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.13.1.9"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-1811(00)00145-6"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-05-1516"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.8.3336.bloodjournal8783336"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm731"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1998.00262.x"},{"key":"e_1_2_6_49_2","first-page":"416","article-title":"Angiogenesis and endothelial cell function","volume":"44","author":"Risau W.","year":"1994","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1038\/74651"},{"key":"e_1_2_6_51_2","first-page":"1447","volume-title":"Fitzpatrick's Dermatology in General Medicine","author":"Belsito DV.","year":"2001"},{"key":"e_1_2_6_52_2","first-page":"209","volume-title":"Liver's Histopathology of the Skin","author":"Cohen LM","year":"1997"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0625.2002.110305.x"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1346-8138.2007.00304.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1346-8138.2007.00304.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T18:22:30Z","timestamp":1697221350000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1346-8138.2007.00304.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,19]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["10.1111\/j.1346-8138.2007.00304.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1346-8138.2007.00304.x","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,19]]}}}